Table 4. Haplotype frequencies between patients and controls and risk estimates for their involvement in colorectal cancer development.
| Gene/Haplotype | % Cases | % Controls | aOR | 95%CI | P |
| COX-2 € | |||||
| A-G-T | 44.9 | 52.4 | 1 | Reference | – |
| G-G-T | 21.9 | 17.3 | 1.51 | 1.10–2.06 | 0.010 |
| A-G-C | 18.3 | 13.4 | 1.57 | 1.13–2.19 | 0.008 |
| A-C-C | 10.3 | 15.1 | 0.82 | 0.56–1.20 | 0.310 |
| HPGD * | |||||
| A-G-A-C | 23.8 | 30.5 | 1 | Reference | – |
| A-G-G-C | 25.4 | 17.8 | 1.70 | 1.22–2.37 | 0.002 |
| A-C-G-T | 17.9 | 20.1 | 1.12 | 0.77–1.62 | 0.550 |
| A-C-G-C | 12.8 | 10.8 | 1.60 | 1.04–2.44 | 0.031 |
| G-G-A-C | 6.4 | 8.0 | 1.05 | 0.57–1.92 | 0.880 |
| SLCO2A1 £ | |||||
| T-C-A-A-A-C | 25.7 | 26.1 | 1 | Reference | – |
| T-A-G-A-A-C | 8.3 | 12.7 | 0.54 | 0.33–0.82 | 0.012 |
| C-C-G-A-A-C | 9.6 | 10.6 | 0.86 | 0.54–1.36 | 0.520 |
| T-C-G-A-A-C | 6.8 | 9.0 | 0.75 | 0.44–1.25 | 0.270 |
| T-C-G-A-G-C | 6.5 | 8.7 | 0.68 | 0.40–1.15 | 0.150 |
| ABCC4 ¥ | |||||
| T-A-T-T-A | 10.9 | 12.0 | 1 | Reference | – |
| T-A-T-C-A | 7.9 | 12.0 | 1.07 | 0.49–2.34 | 0.860 |
| T-G-T-T-A | 7.8 | 10.1 | 1.13 | 0.57–2.24 | 0.740 |
| A-A-T-T-A | 11.6 | 7.5 | 2.28 | 1.12–4.67 | 0.024 |
| T-G-C-T-A | 8.5 | 4.0 | 1.58 | 0.67–3.68 | 0.290 |
| T-G-C-C-A | 4.5 | 6.4 | 0.88 | 0.40–1.96 | 0.760 |
a
Odds ratio (OR) adjusted for age (categorical variable, using the global median age of 60 years as cutoff); CI, confidence interval.
€
SNPs order: rs689466-rs20417-rs5275.
*SNPs order: rs2612656-rs1346271-rs1426945-rs12500316.
£
SNPs order: rs4241362-rs6439448-rs7616492-rs7625035-rs1131598-rs10935090.
¥
SNPs order: rs1751051-rs2274403-rs1678405-rs1678396-rs1751031.